Anti-CBL (phospho Y774) antibody [E160] (ab32446)


  • Product nameAnti-CBL (phospho Y774) antibody [E160]
    See all CBL primary antibodies
  • Description
    Rabbit monoclonal [E160] to CBL (phospho Y774)
  • SpecificityThe antibody detects Cbl phosphorylated on Tyrosine 774.
  • Tested applicationsSuitable for: WB, IHC-P, ICC/IF, Flow Cyt, IPmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    A synthetic phospho-peptide corresponding to residues surrounding Tyr774 of human Cbl.

  • Positive control
    • Jurkat cell lysate and human cervical carcinoma tissue.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

Associated products


Our Abpromise guarantee covers the use of ab32446 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 120 kDa (predicted molecular weight: 99 kDa).
IHC-P Use at an assay dependent concentration.
ICC/IF 1/25.
Flow Cyt 1/20.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

IP 1/20.


  • FunctionParticipates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.
  • PathwayProtein modification; protein ubiquitination.
  • Involvement in diseaseDefects in CBL are the cause of Noonan syndrome-like disorder (NSL) [MIM:613563]. NSL is a syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects.
  • Sequence similaritiesContains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
    Contains 1 RING-type zinc finger.
    Contains 1 UBA domain.
  • DomainThe RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
    The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
  • Post-translational
    Phosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR.
  • Cellular localizationCytoplasm.
  • Information by UniProt
  • Database links
  • Alternative names
    • 4732447J05Rik antibody
    • C CBL antibody
    • Cas Br M (murine) ecotropic retroviral transforming sequence antibody
    • Casitas B lineage lymphoma proto oncogene antibody
    • Casitas B-lineage lymphoma proto-oncogene antibody
    • CBL 2 antibody
    • cbl antibody
    • CBL_HUMAN antibody
    • CBL2 antibody
    • E3 ubiquitin protein ligase CBL antibody
    • E3 ubiquitin-protein ligase CBL antibody
    • Oncogene CBL2 antibody
    • Proto oncogene c CBL antibody
    • Proto-oncogene c-CBL antibody
    • RGD1561386 antibody
    • RING finger protein 55 antibody
    • RNF55 antibody
    • Signal transduction protein CBL antibody
    see all

Anti-CBL (phospho Y774) antibody [E160] images

  • All lanes : Anti-CBL (phospho Y774) antibody [E160] (ab32446) at 1/1000 dilution

    Lane 1 : Jurkat cell lysate
    Lane 2 : Jurkat cell lysate + Pervanadate

    Predicted band size : 99 kDa
    Observed band size : 120 kDa (why is the actual band size different from the predicted?)
  • Immunohistochemical analysis of human cervical carcinoma using ab32446 at 1/25 dilution.
  • Flow cytometric analysis of permeabilized Jurkat cells, untreated (green) or Pervanadate-treated (red), using ab32446 at 1/20 dilution.

References for Anti-CBL (phospho Y774) antibody [E160] (ab32446)

This product has been referenced in:
  • Wakasaki T  et al. A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway. Neoplasia 12:789-96 (2010). WB . Read more (PubMed: 20927317) »
  • Cai J  et al. Diacylglycerol kinase delta and protein kinase C(alpha) modulate epidermal growth factor receptor abundance and degradation through ubiquitin-specific protease 8. J Biol Chem 285:6952-9 (2010). Read more (PubMed: 20064931) »

See all 2 Publications for this product

Product Wall

Jurkat cells were starved overnight, then treated with 50mM Pervanadate for 10min.